10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Tuesday, December 20, 2011

Natco Pharma Ltd:-Buy/sell/growth prospects and recommendation,news and results,target and analysis,view and outlook,multibagger

Scripscan:Natco Pharma Ltd

Story:The Hyderabad-based pharmaceutical company is engaged in the manufacture of active pharmaceutical ingredients and formulations with a focus on oncology. The company owns a retail pharmacy store chain in the US and a small distribution business in Brazil. It is also engaged in contract manufacturing. As part of its marketing strategy, Natco has tied up with leading companies such as Mylan, Dr Reddy''s Labs, Actavis, Breckinridge and Lupin.Net sales and net profit have grown at a CAGR of 20.6% and 17.5%, respectively, in the last five fiscals. The company has been paying dividends since the last five years at an average payout of 10.5%. It plans to spend nearly 5% of its revenues on R&D. The company recently raised Rs 67.5 crore through a qualified institutional placement to fund its expansion plans and meet its working capital requirements. A couple of private equity players have picked up a small stake in the company. Dilip Shanghvi, the promoter of Sun Pharma, has bought a 3.2% stake.Natco Pharma''s stock which had depreciated by 40% in the last 12 months to November, has gained by 20% after the stake deals. With a market capitalisation of Rs 692 crore, the company is valued at one-and-a-half times its consolidated revenues during the last four trailing quarters. These are fair valuations given that the stock is a long-term play for the investors.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner